Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment

Semin Arthritis Rheum. 2017 Aug;47(1):53-64. doi: 10.1016/j.semarthrit.2017.03.022. Epub 2017 Apr 4.

Abstract

Objective: In the present review, the different phenotypes, clinimetric and imaging tools able to assess joint involvement in patients affected by Systemic Lupus Erythematosus (SLE) have been described and summarized. Furthermore, the current knowledge about the pathogenic mechanism and the potential biomarkers of this feature is reported.

Methods: A literature search was done in PubMed, accessed via the National Library of Medicine PubMed interface (http://www.ncbi.nlm.nih.gov/pubmed). Firstly, PubMed was searched using the term "systemic lupus erythematosus" OR "lupus" in combination with (AND) "joint" OR "articular".Secondly, the same PubMed research was combined with other terms, such as "pathogenesis" OR "genetic" OR "antibodies" OR "biomarkers" OR "cytokines" OR "imaging" OR "ultrasonography" OR "magnetic resonance" OR "clinimetry".

Results: After a stringent selection, we evaluated in the present review 13 papers concerning clinical phenotypes of SLE joint involvement, 14 concerning clinimetric assessment, 20 concerning imaging, and finally, 28 concerning pathogenesis and biomarkers. Further relevant data were obtained from the reference lists of articles returned using these search terms and from authors own experience and knowledge of the literature.

Conclusion: Despite the prevalence and severity of SLE joint involvement, more awareness and a deeper evaluation of the clinical heterogeneity of this manifestation are mandatory. Moreover, longitudinal studies are needed to assess the progression of this manifestation and to provide standard definitions and examination/recording protocols.

Keywords: Biomarkers; Clinimetry; Imaging; Joint involvement; Pathogenesis; Systemic lupus erythematosus.

Publication types

  • Review

MeSH terms

  • Abatacept / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis / diagnostic imaging
  • Arthritis / etiology*
  • Biomarkers / analysis
  • Disease Progression*
  • Humans
  • Joints / diagnostic imaging
  • Joints / pathology
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / physiopathology*
  • Severity of Illness Index

Substances

  • Antirheumatic Agents
  • Biomarkers
  • Abatacept